A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
A phase 1/2 trial of REC-1245 in non-Hodgkin lymphoma, run by Recursion Pharmaceuticals Inc., now recruiting.
Overview
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer is a phase 1/2 interventional study registered as NCT06678659 by Recursion Pharmaceuticals Inc., with 170 participants planned, started 2024-11-21 and due to reach its primary completion in 2028-10-30. Interventions recorded: REC-1245.
Similar pages
not linked directly; found by shared links- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialMB-105 in Patients With CD5 Positive T-cell Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialGT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.